The core objective of esophageal cancer surgery is to perform a complete tumor resection with clean microscopic tissue margins (R0 resection) and extensive lymph node dissection (lymphadenectomy). Esophagectomy is utilized for localized and locoregionally advanced esophageal cancer, including both adenocarcinoma and squamous cell carcinoma. Depending on tumor stage and localization, surgery is frequently integrated with neoadjuvant (pre-operative) chemoradiotherapy or perioperative chemotherapy in accordance with international oncology standards such as NCCN and ESMO clinical guidelines.

Esophageal cancer surgery (esophagectomy) is a complex surgical procedure performed under general anesthesia with double-lumen endotracheal intubation for single-lung ventilation. The procedure is executed via open, hybrid, or minimally invasive surgical techniques (MISA/RAMIE). Standard steps include: 1. Surgical Access: Accessing the abdominal cavity via laparotomy or laparoscopy to mobilize the stomach, preserve the right gastroepiploic artery supply, and perform upper abdominal lymphadenectomy (celiac, left gastric, hepatic artery nodes). 2. Conduit Creation: Tubularization of the stomach using linear stapling devices to create a gastric conduit of 3 to 4 cm width. 3. Thoracic Mobilization: Accessing the right pleural cavity via thoracotomy or thoracoscopy to mobilize the thoracic esophagus, resect the surrounding mediastinal tissue en bloc, and perform complete mediastinal lymph node dissection (paratracheal, subcarinal, paraesophageal nodes). 4. Resection and Reconstruction: The pathological section of the esophagus is resected with appropriate proximal margins (>5 cm). The gastric conduit is pulled up into the chest or neck. 5. Anastomosis: A hand-sewn or stapled esophageal-gastric anastomosis is created in the thoracic cavity (Ivor Lewis procedure) or left neck (McKeown procedure). 6. Placement of Drains & Feeding Tube: Placement of thoracic chest tubes, mediastinal drains, and a enteral feeding jejunostomy tube. 7. Closure: Surgical incision closure and patient transfer to the ICU.

Evidence-based outcomes and clinical advantages of definitive surgical resection for esophageal cancer include:

• Definitive Locoregional Tumor Control: Achieving an R0 resection (microscopically negative tumor margins) is the strongest independent predictor of long-term survival in non-metastatic disease (NCCN Guidelines 2023).
• Curative Potential: When integrated with modern multimodal protocols (such as the CROSS trial neoadjuvant chemoradiotherapy regimen or the FLOT trial perioperative chemotherapy regimen), surgery offers 5-year overall survival rates ranging between 45% and 55% for locoregional disease.
• Accurate Pathological Staging: Comprehensive histopathological analysis of the resected specimen and lymph node clearance yield exact pathological stage assessment, identifying complete pathological response (pCR) or indicating post-operative targeted/immunotherapy regimens (e.g., CheckMate 577 adjuvant nivolumab protocol).
• Relief of Malignant Dysphagia: Surgical resection and reconstruction restore functional swallowing capability, eliminating progressive esophageal obstruction caused by primary tumors.

Recovery following esophagectomy occurs across structured chronological phases:

• Inpatient Critical Care (Days 1–3): Intensive monitoring of hemodynamics, mechanical ventilation weaning, pain management via epidural or regional nerve blocks, and initiation of enteral nutrition through a placement feeding jejunostomy tube (J-tube).
• Acute Ward Care (Days 4–10): Removal of thoracic surgical drains, progressive physical therapy and mobilization, chest physiotherapy to prevent atelectasis, contrast swallow study to verify anastomotic integrity, and step-down from intravenous to enteral or oral hydration.
• Early Home Recovery (Weeks 2–6): Home enteral tube feeding supplementation, gradual transition from clear liquids to soft, pureed diets across small, frequent meals, continuous monitoring for delayed surgical site complications or nutritional deficits.
• Long-Term Adaptability (Months 2–12): Gradual gain of lean physical mass, adjustment to altered gastric motility and smaller functional stomach capacity, management of dumping syndrome or reflux symptoms, and routine quarterly surveillance scans.

Esophageal cancer surgery is indicated for several primary neoplasms and precancerous conditions of the esophagus and gastroesophageal junction (GEJ):

• Esophageal Adenocarcinoma: Malignant epithelial tumors arising predominantly in the distal third of the esophagus, often associated with chronic gastroesophageal reflux disease and Barrett's esophagus.
• Esophageal Squamous Cell Carcinoma: Malignant tumors arising from the stratified squamous epithelium, predominantly located in the upper and middle thirds of the thoracic esophagus.
• Gastroesophageal Junction (GEJ) Adenocarcinomas: Specifically Siewert Type I (distal esophageal adenocarcinoma centered 1–5 cm above the anatomical GEJ) and Siewert Type II (true cardia carcinoma centered 1 cm above to 2 cm below the GEJ).
• Barrett's Esophagus with High-Grade Dysplasia (HGD): Severe cellular atypia where endoscopic eradication therapies (such as radiofrequency ablation or endoscopic mucosal resection) are technically unfeasible, unsuccessful, or multifocal.
• Rare Esophageal Neoplasms: Including gastrointestinal stromal tumors (GISTs), neuroendocrine carcinomas, and esophageal leiomyosarcomas requiring radical resection.

Pre-operative preparation for esophageal cancer surgery requires multi-system clinical optimization: 1. Comprehensive Staging: Positron emission tomography-computed tomography (PET-CT) to rule out systemic metastases, high-resolution Endoscopic Ultrasound (EUS) for local T and N staging, and staging laparoscopy for suspected peritoneal disease in gastroesophageal junction tumors. 2. Cardiopulmonary Evaluation: Pulmonary function testing (PFTs including FEV1 and DLCO), baseline arterial blood gas analysis, electrocardiography, and echocardiography to ensure tolerance for single-lung ventilation and major surgical stress. 3. Nutritional Optimization: Assessment of total weight loss and serum albumin; placement of nasojejunal or enteral nutrition if severe malignant dysphagia is present. Pre-operative oral immunonutrition supplements for 5-7 days prior to surgery. 4. Prehabilitation: Daily incentive spirometry, structured aerobic conditioning, and inspiratory muscle training. Complete smoking and alcohol cessation for at least 4 weeks prior to surgery to minimize pulmonary and wound complications.

Esophageal cancer surgery carries high perioperative morbidity. Risks are categorized by clinical severity: 1. Common/Mild Risks: Transient post-operative atrial fibrillation (10–20%), reactive pleural effusions requiring simple drainage, delayed gastric conduit emptying (managed with prokinetics or pyloric balloon dilation), minor surgical site wound infection, and temporary hoarseness. 2. Moderate Risks: Pulmonary complications including hospital-acquired pneumonia, atelectasis, and acute respiratory distress syndrome (ARDS, 10-15%); symptomatic anastomotic stricture formation (10-15% long-term, managed with endoscopic balloon dilation); enteral feeding intolerance. 3. Serious/Rare Complications: Anastomotic leak (5–12%), a major surgical emergency requiring drain placement, endoscopic stent placement, or surgical revision; Chylothorax due to thoracic duct injury (2–5%), requiring dietary fat restriction, octreotide, or duct ligation; Recurrent laryngeal nerve paralysis (3-8%, higher in transhiatal or McKeown techniques); Conduit necrosis (1-2%), requiring emergency conduit resection and delayed reconstruction; In-hospital 30-day mortality (1–3% in high-volume centers, per STS database metrics).

The clinical care pathway for esophageal cancer surgery spans four distinct phases. First, the pre-treatment phase involves multi-modality staging (PET-CT, endoscopic ultrasound, laparoscopic staging), cardiopulmonary functional testing, nutritional optimization, and neoadjuvant therapy when indicated. Second, the surgical phase consists of an inpatient esophagectomy via open, hybrid, or minimally invasive surgical techniques, lasting 4 to 8 hours under general anesthesia. Third, the acute recovery phase requires 1 to 3 days in an intensive care unit followed by 7 to 10 days in a specialized thoracic ward focusing on early ambulation, respiratory therapy, enteral tube feeding, and anastomotic leak screening. Finally, the long-term rehabilitation and surveillance phase involves gradual transition to oral nutrition over 2 to 3 months, lifestyle adaptations, and structured clinical imaging follow-up every 3 to 6 months.